Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$68.98 USD

68.98
1,747,081

+1.03 (1.52%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.

Zacks Equity Research

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

by Zacks Equity Research

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Zacks Equity Research

Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical

by Zacks Equity Research

Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.

Zacks Equity Research

Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.

Zacks Equity Research

Why Is Hologic (HOLX) Down 6.3% Since Last Earnings Report?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.

Zacks Equity Research

Catalent (CTLT) Expands Its Facility Capabilities in Shiga

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.

Zacks Equity Research

Here's Why You Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

Zacks Equity Research

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

Zacks Equity Research

Veeva Systems (VEEV) Offerings Adopted by Minaris Regenerative

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Zacks Equity Research

Zacks Industry Outlook Highlights Hologic, Masimo and Integer

by Zacks Equity Research

Hologic, Masimo and Integer have been highlighted in this Industry Outlook article.

Zacks Equity Research

Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.

Zacks Equity Research

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

Zacks Equity Research

Masimo's (MASI) Platform Expansion to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Industry Challenges

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.

Zacks Equity Research

Boston Scientific (BSX) Gains From Acquisitions, New Launches

by Zacks Equity Research

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Zacks Equity Research

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Zacks Equity Research

Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Accuray's (ARAY) solid product portfolio.

Zacks Equity Research

Veeva Systems' (VEEV) New Tie-Up to Improve Clinical Trials

by Zacks Equity Research

Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Zacks Equity Research

Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management

by Zacks Equity Research

Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.

Zacks Equity Research

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.